Citius Oncology (CTOR) Payables (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Payables data on file, last reported at $6.0 million in Q1 2026.

• On a quarterly basis, Payables fell 47.72% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 47.72% decrease from a year earlier, with the FY2025 full-year figure at $17.0 million, up 126.78% from the prior year.
• Payables for Q1 2026 stood at $6.0 million, down from $6.5 million in the prior quarter.
• Over the last five years, Payables for CTOR reached as high as $17.0 million in Q3 2025 and fell as low as $1.3 million in Q3 2023.
• Historically, Payables has averaged $7.0 million across 4 years, with a median of $6.5 million in 2025.
• Across the five-year window, Payables surged 655.03% in 2025 and plunged 47.72% in 2026, its largest moves.
• Year by year, Payables stood at $1.3 million in 2023, then soared by 632.93% to $9.7 million in 2024, then slumped by 32.81% to $6.5 million in 2025, then decreased by 7.69% to $6.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $6.0 million in Q1 2026, $6.5 million in Q4 2025, and $17.0 million in Q3 2025.